![]() ![]() and changed its name to RAPT Therapeutics, Inc. The company was formerly known as FLX Bio, Inc. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. Its less effective than homeopathic tea tree oil. Short-term (time horizon: 2 weeks) RAPT THERAPEUTICS, INC. Results indicated a MINOR IMPROVEMENT vs placebo. stock price forecast for further price development down to -9.96 (time horizon: 1 day) and price target of 27.81 USD. In afternoon trading, the shares were down 10 at 31.62. These are PHASE 1 result from a study of 31 PEOPLE. RAPT Therapeutics Inc.s shares retreated Wednesday after the biopharmaceutical company priced a roughly 125 million equity raising. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. On June 14th, RAPT announced Phase 1 results for a study on their eczema treatment. #Rapt therapeutics stock forecast trial#Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. ![]() RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |